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SUMMARY 
Anterior Gradient-2 (AGR2) is a component of a pro-oncogenic signalling pathway that 
can promote p53 inhibition, metastatic cell migration, limb regeneration, and cancer 
drug-resistance. AGR2 is in the protein-disulfide isomerase superfamily containing a 
single cysteine (Cys-81) that forms covalent adducts with its client proteins. We have 
found that mutation of Cysteine-81 attenuates its biochemical activity in its sequence-
specific peptide docking function, reduces binding to Reptin, and reduces its stability 
in cells.  As such, we evaluated how chemical oxidation of its cysteine affects its 
biochemical properties. Recombinant AGR2 spontaneously forms covalent dimers in 
the absence of reductant whilst DTT promotes dimer to monomer conversion. 
Mutation of Cysteine-81 to alanine prevents peroxide catalyzed dimerization of AGR2 
in vitro, suggesting a reactive cysteine is central to covalent dimer formation.  Both 
biochemical assays and ESI mass spectrometry were used to demonstrate that low 
levels of a chemical oxidant promote an intermolecular disulfide bond through 
formation of a labile sulfenic acid intermediate.  However, higher levels of oxidant 
promote sulfinic or sulfonic acid formation thus preventing covalent dimerization of 
AGR2. These data together identify the single cysteine of AGR2 as an oxidant 
responsive moiety that regulates its propensity for oxidation and its monomeric-
dimeric state. This has implications for redox regulation of the pro-oncogenic 
functions of AGR2 protein in cancer cells.  
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INTRODUCTION 
Oesophageal adenocarcinoma is thought to develop from pre-malignant lesions termed 
Barrett’s oesophagus [1]. Selection pressures are known to drive p53 gene mutation early in 
oesophageal cancer progression [2]. Whole genome sequencing has determined that 
selection pressures for p53 gene mutations are remarkably confined to a highly specific 
stage, that being Barrett’s tissue associated with high-grade dysplasia [3]. Barrett’s 
epithelium forms a relatively unique microenvironment for the identification of stress activated 
p53 modifiers might place selection pressures on the survival of cells with either p53 gene 
mutation or in maintenance of the wt-p53 alleles [4-6]. Using a proteomics approach in 
Barrett’s epithelium to identify such possible p53 modifiers, a protein named Anterior 
Gradient-2 (AGR2) was identified and validated as an abundant and potent inhibitor of p53-
dependent transcription [7, 8]. AGR2 remains upregulated in a large proportion of 
oesophageal adenocarcinomas [9]. The recent generation of an AGR2 isogenic cell panel 
highlighted p53 pathway suppression as the dominant effect of enhanced AGR2 protein-
dependent remodelling of the proteome [10].  Thus, AGR2 pathway function forms a core 
proteomic landscape whose study might shed light on oesophageal adenocarcinoma 
development as well as p53 pathway silencing. 
 
AGR2 was originally identified as a secretory protein that is highly expressed in Xenopus 
eggs [11]. Apart from its function as a p53 inhibitor [8], subsequent studies have shown a 
significant role for AGR2 in a range of biological pathways including cell migration, cellular 
transformation, metastasis [12] [9], and limb regeneration in vertebrates [13]. Clinical studies 
have also implicated the protein in inflammatory bowel disease [14], hormone-dependent 
breast cancers [15] [16], and in predicting poor prognosis in prostate cancers [17].  The 
molecular mechanisms underlying these wide-ranging biological pathways trigged by AGR2 
are still not completely defined and as the AGR2 gene is confined to vertebrates, the AGR2 
gene pathway cannot be dissected using powerful genetic systems like yeast, flies, or worms 
[18].  However, emerging functions in the AGR2 pathway focus on (i) identifying its client 
proteins as it mediates protein folding in the endoplasmic reticulum [19] and as it stimulates 
receptor maturation [20] [21]; (ii) understanding its function in the endoplasmic reticulum in 
response to unfolded protein responses [22], (iii) defining the nature of its monomer-dimer 
equilibrium in tis chaperone cycle [23]; and (iv) understanding the significance of its highly 
specific peptide docking function which is relatively unique for a molecular chaperone [24] 
[25].  
Endoplasmic reticulum localized molecular chaperones like AGR2 have specific roles that 
enable the folding, trafficking, and assembly of complex cysteine-rich transmembrane 
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receptors with unique protein folding requirements. Reduced glutathione and its oxidized 
counterpart comprise the dominant redox buffer in eukaryotes [26].  A relatively high pro-
oxidizing environment in the endoplasmic reticulum is thought to facilitate the iterative cycles 
of enzymatic cysteine reduction and oxidation on cysteine-rich client receptors destined for 
the secretory system and transmembrane destinations [27]. Classic thioredoxins have a 
conserved thioredoxin fold comprised of the CxxC motif that mediates covalent bond 
formation with cysteine containing client proteins followed by resolution through cycles of 
reduction-oxidation [28]. AGR2 by contrast is part of the thioredoxin superfamily that contain 
CxxS motifs and which lack the ability to exploit a two cysteine redox system that classically 
mediates client protein oxidation and reduction cycles [29]. As such, AGR2 single cysteine 
oxidation and reduction could form an important rate-limiting step in its reaction cycle with 
implications for client protein maturation in human diseases like cancer. In this report, we 
detail the effects of single cysteine mutation on the known core biochemical function of 
AGR2 and also the nature of AGR2 cysteine oxidation on its oligomerization state using 
mass spectrometry (MS). We demonstrate first that cysteine mutation can alter its specific 
activity in protein-interaction assays. Secondly, we demonstrate that low levels of cysteine 
oxidation can induce covalent dimerization through an unstable sulfenic acid intermediate. 
Finally, we show that higher levels of cysteine oxidant yield a sulfinic or sulfonic acid product 
that traps AGR2 in the monomeric and oxidized state. These assays will facilitate future 
dissection of the reaction mechanism of AGR2 as it mediates protein folding of cysteine rich 
client proteins. This may reveal how its oxidation state in the endoplasmic reticulum might 
effects its specific activity as an oncogenic chaperone in the development and maintenance 
of the transformed phenotype. 
 
EXPERIMENTAL PROCEDURES 
General 
All reagents were purchased from Sigma unless otherwise stated. 
 
In Vivo Cross-linking of proteins in MCF7 Breast Cancer Cells 
MCF7 breast cancer cells were cultured in DMEM supplemented with 10% FCS in a 
humidified incubator in 5% CO2 at 37ºC.  For cross-linking, cells were grown to ~90% 
confluence before exposure to DSS (Pierce 21555) or EGS (Pierce 21565).  DSS or EGS 
was dissolve in 100% DMSO to a concentration of 100mM before being further diluted to the 
appropriate concentration in growth media and added to cells.  Cells were incubated for a 
further 1 hour at 37ºC before being harvested into PBS and lysed into the following buffer: 
150mM NaCl, 50mM Tris HCl pH 8.0, 50mM NaF, 5mM EDTA, 1% NP-40 plus 1:100 
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phosphatase inhibitor cocktail (Sigma P5726) and 1:100 protease inhibitor cocktail (Sigma 
P8340).  AGR2 containing cross-linked complexes were detected by Western blot analysis 
using a polyclonal antibody to AGR2 raised in rabbit (Moravian Biotechnology Ltd., Brno 
Czech Republic). 
 
Site Directed Mutagenesis of AGR2 at Cysteine 81 
Human AGR2 was cloned into Invitrogen’s Gateway expression vectors pDEST17 for 
bacterial expression or pDEST12.1 for mammalian expression [8].  Site-directed 
mutagenesis was then carried out on these constructs using Stratagene’s QuickChange® 
Site-Directed Mutagenesis Kit as per manual.  Mutagenic oligonucleotide primers used for 
C81A were as follows; site of mutation underlined: forward: 5’- 
GATTATTCATCACTTGGATGAGGCCCCACACAGTC,reverse:5’- 
GACTGTGTGGGGCCTCATCCAAGTGATGAATAATC. Mutagenic oligonucleotide primers 
used for C81S were as follows; site of mutation underlined: forward: 5’- 
GATTATTCATCACTTGGATGAGTCTCCACACAGTC,reverse:5’- 
GACTGTGTGGAGACTCATCCAAGTGATGAATAATC.  
 
In vivo Cross-linking of Transfected wt and C81A AGR2 
H1299 lung carcinomas cells were cultured in RPMI supplemented with 10% FCS in a 
humidified incubator in 5% CO2 at 37ºC.  One day prior to transfection cells were plated into 
6 well plates (2ml media) so that they would be 90-95% confluent the following day.  Plasmid 
DNA (1μg) encoding either wt or C81A AGR2 and LipofectamineTM 2000 (10 μl) were added 
to two separate volumes of RPMI w/o serum (250 μl) and both were incubated for 5 mins at 
RT.  After this time the two mixtures were combined, gently mixed and incubated at RT for a 
further 20 mins at RT before addition to cells.  Cells were incubated for 24 hours before 
cross-linking was carried out as described above using 1mM DSS. 
 
In vitro Oxidation of Recombinant AGR2 to Form Homodimer 
His-tagged AGR2 purified as described previously [8] was incubated in various 
concentrations of H2O2 for 4 hours at RT.  After this time 4 μg of each reaction was analysed 
by SDS-PAGE carried out w/o the addition of DTT to sample loading buffer.  The resulting 
gel was stained with Coomassie Blue. For mass spectrometry, AGR2 was concentrated to 50 
M in ammonium acetate (100 mM, pH 7.2) before reaction with H2O2. Oxidation was 
allowed to proceed for various times before the addition of 4-fold H2O:MeOH:HCOOH 
(50:45:5) (v/v) quenched the reaction.  Reptin was purified as follows; the gene was cloned 
in frame with an N-terminal precision protease sequence into pDEST15 vector, 
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containing glutathione S-transferase N-terminal tag, expressed into BL21 (DE3) 
competent E. coli cells and grown O/N. The cells were subcultured and induced with 
1M IPTG after OD 0.4 had been reached. After 3 hours the cells were pelleted and 
incubated with lysis buffer (10% sucrose, 50mM Tris (pH 8), 150mM NaCl, 3mg 
Lysozyme, 0.5% NP40, 5mM DTT, 1mM Benzamidine, 20g/ml leupeptin, 1g/ml 
aprotinin, 2g/ml pepstatin, 10g/ml soybean trypsin inhibitor, 1mM EDTA) for 45 
minutes before a 1-minute incubation at 37˚C and sonication on ice. The lysates 
were then centrifuged at 4000rpm for 15 minutes and the supernatant added to 
glutathione sepharose 4B beads and incubated for 2 hours at 4˚C. The beads were 
washed extensively using wash buffer (10 x with 20mM HEPES (pH 7.5), 1mM DTT, 
10% glycerol, 150mM NaCl, ten times with 20mM HEPES (pH 7.5), 1mM DTT, 10% 
glycerol, 1.0 M NaCl, and two times with 20mM HEPES (pH 7.5), 1mM DTT, 10% 
glycerol, 150mM NaCl) before elution buffer (25mM HEPES (pH 7.5), 1mM DTT, 
10% glycerol, 150mM NaCl) containing GST-tagged PreScission protease. The 
mixture was incubated O/N at 4oC and then eluted Reptin was measured for purity 
using an SDS-Coomassie blue stained gel and concentration by Bradford reagent 
(Sigma).  
 
Modification of AGR2 with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NDB-Cl). A solution 
containing 50 M AGR2 in ammonium acetate (100 mM, pH 7.2) was treated with 1 mM 
H2O2 in the presence of 4 mM NDB-Cl. The reaction was allowed to proceed for 45 minutes 
in the dark. H2O:MeOH:HCOOH (v/v/v 50:45:5) was then added to quench the reaction and 
leave the sample at a final concentration of 10 M for MS analysis.  A reaction without H2O2 
was used as a control. 
 
Protein mass spectrometry. Before mass spectrometry analysis each sample was denatured 
with H2O:MeOH:HCOOH (v/v/v 50:48:2), resulting in a protein concentration of approximately 
10 M. Mass spectrometry data was acquired on an apex ultra Qh-FT-ICR mass 
spectrometer equipped with a 12 Tesla magnet and an electrospray ion source (Bruker 
Daltonics, Billerica, MA). Nano-ESI was performed using a TriVersa Nanomate (Advion 
BioSciences, Ithaca, NY) running in infusion mode. Desolvated ions were transmitted to a 6 
cm Infinity cell penning trap.  Trapped ions were excited (frequency chirp 48-500 kHZ at 100 
steps of 25s) and detected between m/z 600 and 3000 for 0.5 s to yield a broadband 512K- 
or 1 Mword time-domain data.  Each spectrum was the sum of 32 mass analyses. The mass 
spectra were externally calibrated using ES tuning mix (Agilent) and analysed using 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 7 
DataAnalysis software (Bruker Daltonics). Isotope distributions of specific charge states were 
predicted using IsotopePattern software (Bruker Daltonics) from theoretical empirical 
formulae. These were overlaid upon the recorded experimental data as scatter plots, with the 
theoretical apex of each isotope peak designated by a circle.    
 
Peptide ELISA to Measure Affinity of wt and mutant AGR2 to Peptide Aptamers and Reptin 
For measuring AGR2 binding to Reptin; the wells of an ELISA plate were coated with 50 μL 
of recombinant Reptin (10 g/mL) overnight at 4⁰C in 0.1M Sodium Carbonate buffer (pH 
9.0). The following day the wells were washed six times with 200 μL of PBST and blocked 
with 200 μL of 3% BSA in PBST for 1 h. A dilution series of either wt or C81A/K95R 
recombinant His-tagged AGR2 was prepared and added to the wells for 1 hr at room 
temperature. The wells were then washed six times with PBST and probed for the presence 
of AGR2 using polyclonal AGR2 antibody diluted 1:2000 in blocking buffer. The reaction was 
detected using swine anti-rabbit HRP monoclonal antibody diluted 1:2000, developed by 
ECL, and read using Fluoroskan Ascent FL.  For measuring AGR2 binding to synthetic 
peptides; the wells of an ELISA plate were coated with 50 μL of streptavidin (2 g/mL in H2O) 
overnight at 37 ⁰C. The following day the wells were washed four times with 200 μL of PBST, 
50 μL of synthetic peptides (D8, E7, or F3; 0.1 mg/mL) was added for 1 hr at room 
temperature, and the wells were washed six times with 200 μL of PBST and blocked with 200 
μL of 3% BSA in PBST for 1 h. The sequences of D8, E7, and F3 are, HLPTTIYYGPPG, 
YPWHHSWTHTTL, and NTSSMPIFSTNR, respectively. A dilution series of either wt or 
C81A/K95R recombinant His-tagged AGR2 was prepared and added to the wells for 1 hr at 
room temperature. The wells were then washed six times with PBST and probed for the 
presence of AGR2 using polyclonal AGR2 antibody diluted 1:2000 in blocking buffer. The 
reaction was detected using swine anti-rabbit HRP monoclonal antibody diluted 1:2000, 
developed by ECL, and read using Fluoroskan Ascent FL. 
 
Accumulation of Transfected AGR2 after MG132 Treatment 
HCT116 colon cancer cells (wt-p53 and isogenic p53-null cells) were cultured in McCoy’s 5A 
media supplemented with 10% FCS in a humidified incubator in 5% CO2 at 37ºC.    One day 
prior to transfection cells were plated into 6 well plates (2ml media) so that they would be 90-
95% confluent the following day.  Transfections were carried out using Attractene 
transfection reagent (Qiagene).  Either wt or C81A AGR2 or empty vector control (0.6μg) and 
Attractene (2.25μl) were added to media w/o serum to a final volume of 500 μl and incubated 
at RT for 10 mins before being added to the cells and incubated for 24 hours.  After this time 
media was removed and replaced with fresh media containing either 0 or 10 μM MG132 
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(Calbiochem) and incubated for a further 5 hours.  Cells were then harvested, lysed and 
AGR2 levels were measured by Western blot as described above. 
 
RESULTS  
Cys81 mutation affects the biochemical and cellular stability of AGR2 protein. 
Dimer to monomer stability can regulate the specific activity of AGR2 in protein-binding 
assays; most notably, deletion of its N-terminal dimer instability domain can increase its 
activity [30]. We first aimed to develop an understanding of whether mutation of Cys81 
affects the AGR2 dimer-monomer equilibrium of AGR2.   The use of amino acid-reactive 
chemicals were initially used as tools to define dimerization determinants. The cell 
membrane permeable cross linker DSS (but not EGS) induced a predominant dimerization of 
AGR2 in cells (Figure 1A). We observed that this DSS-mediated chemical oxidation occurs 
equally well in wild-type AGR2 or the AGR2C81A cysteine mutant (Figure 1B) indicating that 
DSS mediated dimerization in cells does not proceed through cysteine oxidation. This is 
consistent with previous data showing that in vitro, the DSS reactive cross-link that stabilizes 
AGR2 dimerization maps to K95[30]. These data also indicate that mutating Cys81 does not 
alter the fixed distance between Lys95 residues in the AGR2 dimer that facilitate DSS-
dependent cross-linking. In addition, we noticed that the AGR2C81A mutant protein exhibited 
reduced steady state levels than wt-AGR2 (Figure 1B, lanes). As such we evaluated whether 
the instability of the AGR2C81A mutant protein was proteasome dependent; indeed the lower 
steady state levels of the AGR2C81A mutant protein were elevated by the proteasome inhibitor 
MG132 (Figure 1C). These data suggests that in vivo modification of Cys81 of AGR2 could 
alter its steady state levels. 
 
Next we evaluated whether there are any differences in the specific activity of AGR2 as a 
function of Cys81 mutation. First, we observed that the AGR2C81A mutant protein is defective 
in binding to the chaperone protein Reptin (Figure 1D). Similar loss of binding to Reptin was 
observed when using the AGR2K95R mutant protein (Figure 1D). The biochemical activity of 
the AGR2C81A mutant protein towards its consensus peptide-docking site was also reduced 
compared to wt-AGR2 (Figure 1E). As such, we focused in this study on measuring whether 
the more physiologically relevant cysteine oxidation can impact on the dimeric subunit 
structure of AGR2.  
 
Oxidation-dependent dimerization of AGR2 dependent upon Cys81  
To evaluate the effects of cysteine oxidation on AGR2 dimer stability, we purified his-tagged 
AGR2 (larger mass than untagged AGR2 due to the amino acid tag) in the absence of 
reducing agent (normally used during purification) that resulted in the accumulation of a 
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larger molecular mass species of approximately twice the mass of his-tagged AGR2 (Figure 
2A, lane 1). The incubation of the sample with the reducing agent DTT resulted in collapse of 
the ~48 kDa species (Figure 2A, lane 2 vs 1) suggesting a cysteine-dependent covalent 
dimer was formed under pro-oxidizing conditions. AGR2 protein has one reactive cysteine at 
codon 81 (Figure 2B) and mutation of this amino acid to alanine prevented the spontaneous 
oxidation-dependent dimerization (Figure 2C, lane 3 vs 1).   
 
In order to determine whether the covalent dimeric form of AGR2 can form through such an 
oxidation, we needed to set up an in vitro oxidation system that can be used to monitor 
quantitatively covalent dimerization of reduced and monomeric AGR2 protein. A titration in 
vitro of H2O2 into a solution with reduced AGR2 protein results in the appearance of dimeric 
AGR2 (Figure 3A, lane 2 vs 1), whilst at concentrations greater than 200 M the dimerization 
was attenuated (Figure 3A, lane 5-9 vs lane 2-4). A titration of H2O2 at reduced 
concentrations demonstrates that dimerization is promoted from a concentration of 5-100 M 
(Figure 3B, lanes 5-8 vs lanes 1).  The use of AGR2C81S and AGR2C81A mutant proteins 
confirmed that the peroxide induced dimerization was dependent upon Cys81 (Figure 4A-C). 
These data provide a dynamic assay that can be used to chemically oxidize reduced AGR2 
to either promote dimerization at low H2O2 concentrations or to prevent AGR2 dimerization at 
elevated concentrations of H2O2.  This suppression of AGR2 oxidation at elevated 
concentrations of H2O2 suggests a mechanism whereby oxidation levels can regulate the 
conversion of AGR2 monomer to dimer. This might prove in future to have effects in cells on 
the specific activity of AGR2 in pro-oxidizing environment of the endoplasmic reticulum.  
 
Oxidation-dependent dimerization of AGR2 through direct Cys81 modification 
We next set out to determine whether, indeed, chemical evidence can be obtained for direct 
Cys81 oxidation through a Cys81-Cys81 cross link but also to explain why higher 
concentrations of oxidant prevents AGR2 covalent dimerization. ESI mass spectrometry was 
used to determine whether such a reaction mechanism could be developed by analysing 
changes in molecular mass of full-length AGR2 as a function of increasing oxidant and 
therefore whether evidence could be found for dimerization through a disulfide bond or 
through a distinct amino acid.  
 
The AGR2 protein used has an N-terminal histidine-tag (Figure 5A). After rapid replacement 
of reduced his-tagged AGR2 protein in ammonium acetate buffer a H2O/MeOH/HCOOH 
electrospray make-up solvent was added in order to denature the protein before direct 
infusion MS analysis. The protein showed a charge distribution from [M+12H]12+ to 
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[M+24H]24+  (Figure 5B and Figure 6) with an nominal average mass of 21,041 Daltons for 
the cysteine-reduced protein. Analysis of the isotope distribution of the [M+20H]20+ charge 
state is consistent with the theoretical isotope distribution of monomeric AGR2 containing 
one reduced cysteine residue [C944H1506N258O277S5]
20+ (Figure 5B, insert).  Gel filtration 
confirmed that AGR2 protein in the reduced state does not form a stable homodimer (data 
not shown; [30]). A titration of AGR2 with the oxidant H2O2 was performed and monitored by 
mass spectrometry, which resulted in the appearance of a second species in the mass 
spectrum. This species displayed a charge state distribution from [M+23H]23+ to [M+31H]31+, 
and a nominal average mass of 42079 Da; the signals of these ions were elevated in 
response to increasing oxidant (Figure 6).  This observation is consistent with the formation 
of a dimeric AGR2 species, as suggested using gel electrophoresis (Figure 3 and 4). Indeed, 
an expanded spectrum of the ion at [M+27H]27+ charge state is consistent with the theoretical 
isotope distribution of an AGR2 dimer containing one intermolecular disulfide bond 
[C1888H2997N516O554S10]
27+(Figure 7A and B). These data together indicate that the reactive 
cysteine plays a direct role in covalent dimer formation (Figure 7C).  
 
Interestingly, the additions of higher levels of oxidant prevent dimer formation (Figure 4). To 
investigate why dimerization might be suppressed at higher oxidant concentrations, we also 
analysed this reaction mechanism using mass spectrometry. Expanded analysis of the ions 
isolated with a [M+15H]15+ charge state at higher oxidant concentrations resulted in the loss 
of the dimer and accumulation of ions with monomeric mass consistent with the addition of 
two oxygen atoms [C944H1501N258O279S5]
15+, suggesting oxidation of the cysteine residue 
within AGR2 to the sulfinic acid, Cys-SOOH (Figure 8A and B). The highest concentrations of 
oxidant also yielded a species with three additional oxygen atoms, [C944H1501N258O280S5]
15+, 
consistent with formation of sulfonic acid, Cys-SO3H (Figure 8A).  
 
It is clear from the above results that, within AGR2, Cys-81 is susceptible to oxidation by 
peroxide. We have demonstrated that with excess peroxide treatment Cys-81 is readily 
oxidised to a sulfinic acid. However, under mild peroxide condition (< 200 M), oxidation 
favours disulfide bond formation – resulting in an AGR2 dimer covalently coupled via an 
intermolecular disulfide bond. Both H2O2 mediated disulfide bond formation and over-
oxidation of cysteine to sulfinic acid are thought to proceed through a labile sulfenic acid 
intermediate (Cys-S-OH). Species containing this oxidation state of cysteine are generally 
highly reactive and unstable to the ESI process making them unsuitable for MS analysis. 
However, it is known that the electrophilic agent NBD-Cl reacts specifically with both Cys-SH 
and Cys-S-OH to produce Cys-S-NDB adducts and Cys-S(O)-NDB adducts respectively, 
both with mass +163 Da (Figure 9A) [31]. Crucially, upon reaction with NBD-Cl, the oxygen 
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atom from a sulfenic acid is retained within the product; producing a mass label that is stable 
to ESI-MS. Reduced or oxidized AGR2 protein was incubated with NBD-Cl prior to infusion 
for analysis using mass spectrometry. Under these conditions, the protein with charge state 
of [M+18H]18+ had an increase in mass of 162.963 Da (Figure 9B) which is consistent with a 
single NBD adduct.  The oxidized AGR2 mass at this charge state was elevated by 178.982 
Da (Figure 9B) which is consistent with the trapping of an unstable sulfenic acid intermediate 
(Figure 9B). Together, these MS observations allow us propose a mechanism for peroxide-
mediated dimer formation and propose a mechanism whereby excessive cysteine oxidation 
prevents dimer formation (summarized in Figure 10).  
 
DISCUSSION 
Our experiments aimed to define how the single cysteine in AGR2 impacts on its protein 
binding activity and oxidation-dependent dimerization. In this report, we first developed an in 
vivo assay that demonstrates that AGR2 appears to exist in a non-covalent dimeric state as 
defined by the ability of DSS to cross link AGR2 into a homo dimer (Figure 1A). This in vivo 
cross-link might occur through Lys95-Lys95 adducts (mapped in vitro [30]) and not through 
Cys81-Cys81 adducts (Figure 1B).  However, the titration of the chemical oxidant peroxide 
suggested that AGR2 can assemble into a distinct dimeric structure that is mediated through 
a Cys81-Cys81 covalent bond (Figure 4). The discovery that AGR2 forms an oxidation 
responsive dimer opens the door to begin to analyse this fundamental property of AGR2 
homodimer on its cell physiology. Mutation of the reactive cysteine to alanine reduced the 
specific activity of AGR2 in sequence-specific peptide-aptamer binding and in Reptin protein-
binding assay (Figure 1D and E).  This mutation also changes the in vivo stability of AGR2 
(Figure 1C).  
 
Mass spectrometry is a powerful tool for the characterisation of protein modifications by the 
monitoring molecular mass of the intact protein species; for example we have previously 
used this technique to define the stoichiometry of methylation and acetylation on native 
histones purified from HCT116 colon cancer cells [41] and to characterise reactive cysteine’s 
on the p53 tumour suppressor [42].  In this current report, mass spectrometry was used to 
define the nature of the covalent modifications on AGR2 as a function of increasing oxidant 
concentration. Mass spectrometry has also been previously used to define the mechanism of 
sulfonucleotide reduction by sulfonucleotide reductase [43]. We were able to distinguish 
between a two models that invoked a reaction mechanism involving the reduction of an inter-
molecular disulfide in a dimeric structure or an intramolecular disulfide bond in a monomeric 
form of the enzyme prior to nucleophilic attack on sulfonucleotides to form an enzyme-
thiosulfonate intermediate.  Covalent dimerization via disulfide bond formation appears to be 
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a increasingly important physiological mechanism involved in regulating signalling proteins. 
The adhesion factor E-cadherin can also form a DTT-sensitive dimer with dimerization 
driving the degradation of the protein in cells [44]. By contrast, dimerization of AGR2 appears 
to have physiological significance since the monomeric mutant protein (C81A) was 
significantly de-stabilized through the proteasome pathway in HCT116 colon cancer cells 
(Figure 1C). In turn, changes in AGR2 steady state levels in cells might regulate some of the 
many biological functions of AGR2 including cell migration, transformation, or p53 inhibition.  
Specifically, since the dimer to monomer conversion in AGR2 is responsive to the redox 
state of the protein, this suggests that in a pro-oxidizing environment like that observed in 
cancer cells and/or in the endoplasmic reticulum, AGR2 oxidation states might yield diverse 
regulatory pools of the protein. This has implications for AGR2 binding to Reptin in the 
cytosol since the cysteine mutation in AGR2 severely impacts on Reptin Binding (Figure 1). 
Indeed, it is interesting that AGR2 is more able to inhibit p53 protein activity after cells have 
been subjected to a pro-oxidizing stress of UVC irradiation [8] or cisplatin [10]. Additionally, 
AGR2 is also able to mediate export of p53 from the nucleus into the cytoplasm better upon 
UVC irradiation [25]. UVC is a known pro-oxidizing stimulus in cells [45, 46] and these data 
allow a model to be developed that proposes AGR2 protein activity might be stimulated by 
stresses present in a pro-oxidizing environment revealing a potentially physiological role for 
dimer assembly in AGR2-mediated oncogenesis.  
 
Lastly, a recent report has confirmed that AGR2 is a PDI that is essential for the production 
of the intestinal mucin MUC2, a cysteine-rich glycoprotein that forms the protective mucus 
gel lining the intestine [35]. This agrees with other reports suggesting that AGR2 plays a role 
in mucus secretion [36] (and European patent WO/2004/056858). This is a major function of 
goblet cells and producing this protective mucus layer can have an impact in inflammatory 
bowel disease through inhibition of bacterial entry into intestinal cells.  The cysteine residue 
within the AGR2 thioredoxin-like domain was shown to form mixed disulfide bonds with 
cysteines in the N-terminus or C-terminus of MUC2 as the receptor  is being processed [35].  
Thus we would expect that irreversible oxidation of AGR2 would impact upon mucin 
secretion and/or that there exist chemical control mechanisms in the ER that minimize 
sulfinic or sulfonic acid formation. This might involve other CxxC containing PDIs that prevent 
irreversible oxidation of AGR2. It remains to be determined if AGR2 interacts with such CxxC 
containing PDIs.  Such control of AGR2 might be important for regulating inflammatory bowel 
disease, as AGR2-/- mice are highly susceptible to chemically-induced acute colitis [35]. 
Further studies are required to precisely determine how dietary chemicals or intracellular 
oxidation of AGR2 impacts its ability to interact with cysteine-rich client proteins like MUC2.  
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FIGURE LEGENDS 
 
Figure 1. Mutation of AGR2 at Cys81 alters its properties. (A). In vivo treatment of living 
cells with cell-membrane permeable homobifunctional N-hydroxysuccimide esters.  MCF7 
cells grown in media with 10% FCS were incubated with increasing concentrations of the 
cell-membrane permeable cross-linkers DSS (lanes 2-5) or EGS (lanes 6-9) for 1 hour at 
37oC.  Cells were harvested, lysed using a Tris-HCl (pH 8.0) buffer containing 1% NP-40, 
lysates were separated by electrophoresis, and protein was immunoblotted to determine 
whether intermediary species of AGR2 could be detected under conditions where the 
majority of AGR2 was not cross-linked. Higher molecular mass adducts that react with the 
AGR2 antibody is highlighted by arrows. (B).  Mutation of AGR2 at Cysteine-81 does not 
prevent in vivo dimerization induced by DSS. H1299 cells were transfected with expression 
vectors including; vector only control (lanes 1), encoding wt-AGR2 (lanes 2 and 3), or 
AGR2C81A protein (lanes 4 and 5). Cells were incubated with DSS and lysates were 
immunoblotted to examine extent of AGR2 cross-linking. The arrows highlight monomeric 
and dimeric AGR2 protein. (C). The C81A mutation in AGR2 sensitizes to proteasome-
dependent degradation in vivo in HCT116 colorectal cancer cells. Vectors expressing wt-
AGR2 or AGR2C81A were transfected into HCT116 cells (lanes 1-6) or isogenic p53-null 
HCT116 cells (lanes 7-12). Twenty fours hours later, cells were treated with the proteasome 
inhibitor MG132 (as indicated by +) and cells were harvested for immunoblotting: AGR2; p53; 
and Actin loading control.  (D and E). Effects of C81A mutation of AGR2 on its Reptin and 
peptide-binding activity. (D) Fixed amounts of Reptin (500 ng/well) were absorbed onto 
ELISA wells or (E) fixed amounts of the indicated biotinylated peptides (D8 and E7 are AGR2 
binding peptides and F3 is a non-specific control) were adsorbed onto the streptavidin solid 
phase. Next, wt-AGR2, AGR2K95R or AGR2C81A (C2A mutant) proteins were titrated to 
measure relative binding affinities of AGR2 towards (D) Reptin or (E) the indicated synthetic 
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peptides using anti-AGR2 antibody. The data are plotted as extent of AGR2 binding (RLU) as 
a function of AGR2 titration (g).  
 
Figure 2. A reactive cysteine mediates covalent dimerization of AGR2.  (A). In vitro 
oxidation of AGR2 promotes homodimerization. Recombinant his-tagged AGR2 protein (100 
ng) was incubated without reducing agent (DTT; lane 1) or with DTT  for 1 hour at 37oC (lane 
2) prior to electrophoresis. Samples were immunoblotted for examining changes in the 
denatured mass of AGR2 protein. (B). Primary amino acid sequence of AGR2 with Cysteine 
81 highlighted. (C). Mutation of Cyteine-81 prevents oxidation induced AGR2 dimerization. 
Recombinant his-tagged wt- AGR2 protein (lanes 1, 2, 4 ,and 5) or AGR2C81A protein (lanes 
3, 4, 7, and 8) were incubated without or with reducing agent (DTT), as indicated. Samples 
were immunoblotted for examining changes in the denatured mass of AGR2 protein.  
 
Figure 3.  Oxidant-induced dimerization of AGR2. AGR2 protein was incubated with the 
indicated concentrations of hydrogen peroxide ((A) 0-10 mM and (B) 0-500 M]), reactions 
were quenched using SDS sample buffer (without DTT), samples were separated by 
electrophoresis, and then stained with Coomassie blue. The arrows indicate position of 
monomeric and dimeric AGR2.  
 
Figure 4. A reactive cysteine mediates covalent peroxide-induced dimerization of 
AGR2. AGR2 protein (wild type, C81A or C81S) were incubated with the indicated 
concentrations of hydrogen peroxide (H2O2), reactions were quenched using SDS sample 
buffer (without DTT), samples were separated by electrophoresis, and then stained with 
Coomassie blue. The arrows indicate position of monomeric and dimeric AGR2 
 
Figure 5. Intact Mass Spectrometry analysis of histidine-tagged AGR2. (A) Amino acid 
sequence of AGR2 with the histidine tag (underlined), the theoretical empirical formula 
(without N-terminal methionine residue) is highlighted. (B) AGR2 protein affinity purified form 
nickel-agarose column was buffer exchanged into 100 mM Ammonium Acetate (pH 7.2) and 
the protein concentration was adjusted to 0.5 mg/ml. Aliquots (10 l) were mixed with 20 l of 
a electrospray make-up solvent containing 45% methanol and 5% formic acid. Samples were 
directly infused and analysed by nESI MS. The data depicts the charge state distribution. 
Analysis of the isotope distribution of the [M +20H]20+ charge state is highlighted, insert.  
 
Figure 6. Effects of oxidant titration on the charge state distribution of AGR2 protein. 
AGR2 protein (50 M) affinity purified form nickel-agarose column was buffer exchanged into 
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100 mM Ammonium Acetate (pH 7.2), incubated with the indicted concentrations of the 
oxidant H2O2 (final concentration 6.2 M to 2.5 mM) for 20 minutes before the reaction was 
terminated using a 3x volume of electrospray make-up solvent. Samples were directly 
infused and analysed by nESI MS. Data depicts the mass-charge distribution (from 
[M+20H]20+ to [M+12H]12+) of AGR2 highlighted as a function of H2O2 concentration. Dose 
dependent formation of a dimeric species was observed with increasing oxidant 
concentration. Charge states corresponding the dimeric species are highlighted in red (from 
[D+31H]31+ to [D+23H]23+). 
 
Figure 7. Conversion of AGR2 from monomer and dimer state monitored by mass 
sepctrometry. (A) Appearance of the 27+ charge state of AGR2 dimer,[D+ 27H]27+,as a 
function of oxidant concentration. Consistent with an AGR2 dimer containing an 
intermolecular disulfide bond. (B) Isotope distribution of the [D+ 27H]27+ charge state of 
AGR2. The theoretical isotope distribution is overlaid as a scatter plot. (C) Diagram of 
disulfide bond formation.  
 
Figure 8. Conversion of AGR2 from reduced monomer to monomeric sulfinic/sulfonic 
acid isoform. (A) Expanded mass-charge analysis of the AGR2 [D+30H]30+ /[M+15H]15 
charge state; Appearance of species consistent with [M+2O+15H]15+ (sulfinic acid; 
highlighted in blue) and [M+3O+H]30+(sulfonic acid; highlighted in orange) are observed at 
higher oxidant concentration.  (B) Expanded mass-charge analysis of the [M+20H]20+ charge 
state highlighting the +32 Da mass shift which occurs upon 2.5 mM H2O2 treatment of AGR2.  
(C) This modification is attributed to oxidation of cysteine to sulfinic acid within the AGR2 
monomer.  
 
Figure 9. Evidence for sulfenic intermediate in the oxidation of AGR2 protein. (A). 
Theoretical effects of NBD-Cl modification of cysteine thiols and cysteine sulfenic acids 
which results in a mass of +163 Da. Depicted are the cysteine thiol adduct and the labile 
sulfenic acid intermediate adduct.  (B). Analysis of the [M+18H]18+ charge state of  of AGR2 
protein monomers with distinct cysteine NBD-modifications.  AGR2 protein (50 M) was 
treated with 4 mM NDB-Cl with out without 0.1 mM H2O2. The reaction continued for 45 
minutes in the dark prior to quenching with a 3x electrospray make-up solvent containing 
45% Methanol and 5% formic acid.  The mass/charge spectrum of the [M +18H]18+ charge 
state of AGR2 protein highlights the unmodified protein (top panel); the thiol modified protein 
(middle panel; 163.963 Da); and a significant amount of the sulfenic-trapped intermediate 
(bottom panel; 178.982 Da).  
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Figure 10. Distinct isoforms of AGR2 protein can be produced through cysteine 
oxidation. Oxidation produces a reactive sulfenic acid intermediate that reacts 
intermolecularly with a reduced AGR2 monomer to form a dimeric covalent complex. Higher 
levels of oxidant promote the formation of a sulfinic acid that cannot form homodimers or with 
the highest level of oxidant leading to the formation of the sulfonic acid.  These isoforms 
might have distinct specific activities in protein-protein interactions and in mediating client 
protein maturation.  
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Highlights 
 AGR2 is an ER resident chaperone that mediates cysteine-rich receptor maturation 
 Mutation of its single cysteine attenuates its protein-protein interaction function 
 AGR2 dimerizes by two distinct mechanisms, one of which is through cysteine 
oxidation 
 Oxidation dimerizes AGR2 through a labile sulfenic acid intermediate  
 High level oxidation induces a sulfinic or sulfonic acid preventing dimerization  
 Differential AGR2 oxidation has the potential to impact on its chaperone function 
